Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Larry Dillaha"'
Publikováno v:
Pain Practice. 16:1012-1018
Objective To further describe effective dose titration of fentanyl sublingual spray to treat breakthrough cancer pain (BTCP) during the 26-day open-label titration phase of a phase 3, randomized, double-blind, placebo-controlled study. Methods Opioid
Publikováno v:
Future cardiology. 12(6)
Aim: To evaluate tolerability of a new extended-release acetylsalicylic acid (ER-ASA). Materials & methods: Daily ER-ASA (162.5–1300 mg) for up to 6 weeks was evaluated (four studies; n = 565). Safety of ER-ASA, immediate-release (IR; 150–1200 mg
Autor:
Richard Rauck, Lowell Reynolds, Jonathan Geach, Neha Parikh, Janet Bull, Larry Dillaha, Morris Scherlis, Lisa Stearns
Publikováno v:
Current Medical Research and Opinion. 28:859-870
A number of transmucosal fentanyl formulations have been developed for the management of breakthrough cancer pain (BTCP). Sublingual delivery of fentanyl, formulated as fentanyl sublingual spray, offers the potential for more rapid and greater absorp
Publikováno v:
Postgraduate medicine. 127(6)
Low-dose acetylsalicylic acid (ASA; aspirin) for secondary prevention reduces cardiovascular disease mortality risk. ASA acetylates cyclooxygenase in the portal circulation and is rapidly (half-life, 20 min) hydrolyzed. Certain patients with cardiova
Publikováno v:
Journal of opioid management. 10(4)
Objective: To examine the relationship between the dose of fentanyl sublingual spray needed to control breakthrough cancer pain (BTCP) and the dose of around-the-clock (ATC) opioid used to control background pain . Design: Analysis was based on the o
Publikováno v:
Clinical drug investigation. 33(6)
Fentanyl sublingual spray is a novel formulation of fentanyl for sublingual delivery that was designed to enhance the rate and extent of absorption of fentanyl for management of breakthrough cancer pain (BTCP). The primary objective of this study was